Evidence map›Paper›PMID 39072331›Full record

ArticleFrontiers in immunology2024

SOX combined with apatinib and camrelizumab in the treatment of resectable locally advanced gastric cancer: a case report.

JiKe Hu, Xuemei Li, Yunpeng Wang, Bo Xu, Puyi He, Zhuanfang Wang, Lijuan He, Hao Chen

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

JiKe Hu *The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.
Xuemei Li *The Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.
Yunpeng WangThe Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.
Bo XuThe Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.
Puyi HeThe Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.
Zhuanfang WangThe Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.
Lijuan HeThe Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.
Hao ChenThe Second Hospital and Clinical Medical School, Lanzhou University, Lanzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Gastric cancer is highly prevalent in China, yet early diagnosis and overall survival rates are low. The primary treatment strategy is comprehensive therapy centered on surgery. Studies indicate that neoadjuvant chemotherapy can enhance radical resection rates and extend survival in locally advanced gastric cancer. Combining VEGFR inhibitors with chemotherapy improves efficacy in digestive system tumors, while PD-1/PD-L1 inhibitors combined with anti-angiogenesis agents or chemotherapy show synergistic effects. This report presents a case of gastric adenocarcinoma (cT3N1M0) treated with SOX, apatinib mesylate, and camrelizumab as neoadjuvant therapy, followed by D2 distal gastrectomy and postoperative adjuvant therapy with the same regimen. The patient completed all treatment cycles successfully. Post-neoadjuvant therapy, only focal residual cancer cells were found in the lamina propria (pT1a). During postoperative adjuvant therapy follow-up, gastroscopic biopsy indicated a pathological complete response with no recurrence or metastasis. The patient primarily experienced dyspepsia, oropharyngeal pain, capillary proliferation, mild bone marrow suppression, nausea, and vomiting as side effects. Therefore, SOX combined with apatinib mesylate and camrelizumab shows promise for treating resectable locally advanced gastric cancer.

Indexed as

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsPyridinesStomach NeoplasmsAdenocarcinomaGastrectomyHumansMaleMiddle AgedNeoadjuvant TherapyTreatment OutcomeAntibodies, Monoclonal, HumanizedapatinibcamrelizumabPyridinesapatinib mesylatecamrelizumabcase reportlocally advanced gastric cancerSOX

Identifiers

PMID39072331
PMCPMC11272450

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.